Predict your next investment

Enterasense company logo
HEALTHCARE | Medical Devices & Equipment / Surgical Devices

See what CB Insights has to offer

Founded Year



Grant | Alive

Total Raised


Last Raised

$2.87M | 3 yrs ago

About Enterasense

EnteraSense has developed a capsule that can detect bleeding in the gastrointestinal tract. Post-surgical patients who are at risk of further bleeding can have the capsule attached to their stomach to monitor and detect bleeding and thus ensure they get appropriate and quick treatment if needed.

Enterasense Headquarter Location

15-16E Mervue Business Park Mervue

Galway, H91 D3T0,


091 750 246

Latest Enterasense News

Galway medtech start-up EnteraSense secures €3.5 million funding - Galway Daily

Jan 7, 2019

Galway medtech start-up EnteraSense secures €3.5 million funding The Galway based medtech start-up company EnterSense has secured €3.5 million in funding from private investments and EU grant aid. Founded in 2015, EnteraSense is working on a diagnostic tool to easily detect bleeding in the gastrointestinal tract. It consists of a capsule the patient ingests, and an external receiver and has shown promise in initial tests. They first licensed the technology from Harvard University, and will use this funding to further develop and commercialise the product. According to the Irish Times, the funding they have secured consists of €2.5 million grant from the EU’s Horizon 2020 programme, and €1 million from varied investors. EnteraSense was founded by veteran medtech investor Donal Devery, who has previously set up biomedical company Vysera Biomedical and was CEO of Galway medtech test lab Anecto. Other founding members include Dr Chris Thompson of Brigham and Women’s Hospital and Harvard Medical School, and Dr Marvin Ryou of Brigham and Women’s Hospital. The private investors they have brought in so far include physicians from the United States, an Irish equity fund, Dubai investors, and local Galway business people. It has also been supported by Enterprise Ireland . Donal Devery said the fact that physicians are among their investors shows just how much promise their product has from a medical standpoint. They hope to go looking for regulatory approval for the device’s use by mid-2020. “We want to improve patient outcomes and drive cost down for the health system,” said Mr Devery. “Each process and function within the deliverables associated with the grant will help us achieve this goal.” Tags

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Enterasense

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Enterasense is included in 1 Expert Collection, including Medical Devices.


Medical Devices

7,892 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

Enterasense Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Enterasense Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.